SIGMA-VB: Validity and reliability of the Brazilian Portuguese version of the Montgomery-Åsberg Depression Rating Scale using the Structured Interview Guide for the MADRS

Fernandes, Fernando; Carneiro, Adriana Munhoz; Campos, Rodolfo Nunes; Soeiro-de-Souza, Márcio G.; Barros, Vivian Boschesi; Moreno, Ricardo Alberto

doi:10.1590/1516-4446-2018-0105

Cited by 10 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients treated at these 2 centers were of any sex, aged 18 years or greater, with a Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition , Text Revision , diagnosis of unipolar psychotic major depressive disorder confirmed by the Brazilian version of the Mini International Neuropsychiatric Interview 5.0.0—MINI Plus at the time of treatment 23 . Individuals were included in this chart review if they had a depression severity score of 20 or greater in the Montgomery-Åsberg Depression Rating Scale (MADRS) 24 at baseline and were not included if they met any of the following criteria: other diagnoses of major mental health conditions such as bipolar depression and schizophrenia; were treated with other interventions such as ECT, vagal nerve stimulation, or transcranial magnetic stimulation within the last 6 months; or were diagnosed with intellectual disability or dementia.…”

Section: Methodsmentioning

confidence: 99%

Esketamine for Unipolar Major Depression With Psychotic Features

Souza-Marques

Telles

Leal

et al. 2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purposes/BackgroundThe aims of the study were to assess subanesthetic esketamine as an antidepressant for major depressive disorder with psychotic features (PMDD) and to compare posttreatment symptoms among those with PMDD to a sample of nonpsychotic depression (major depressive disorder [MDD]).Methods/ProceduresThis study is a retrospective chart review of patients with major depression and current psychotic symptoms, treated with a single parenteral 0.5-mg/kg dose of esketamine. Depression symptoms were assessed at baseline and 24-hour posttreatment with the Montgomery-Åsberg Depression Rating Scale. Individuals with PMDD were matched in a 1:2 ratio to nonpsychotic MDD patients from a randomized, noninferiority clinical trial of esketamine.Findings/ResultsA total of 15 individuals with PMDD were included, which had higher baseline depression scores (PMDD = 40.9, MDD = 33.6, P = 0.004). A statistically significant change in depressive symptoms was found for the PMDD sample (β = −16.20 [95% confidence interval, −23.30 to −9.10], P < 0.001), and no difference between PMDD and MDD groups was observed in the matched-sample analysis (β = −2.2 [95% confidence interval, −9.32 to 4.58], P = 0.537). Treatment-induced dissociative symptoms were present for both groups, self-contained to within 2 hours after treatment, and no exacerbation of psychotic symptoms was found in clinical assessments.Implications/ConclusionsResults suggest a single 0.5-mg/kg dose of esketamine may benefit individuals with PMDD, and the symptom reduction may be comparable with esketamine's effects for MDD. Furthermore, esketamine may induce an antidepressant response in those with PMDD without complication of psychotic symptoms. Future research with controlled designs is warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Esketamine for Unipolar Major Depression With Psychotic Features

Souza-Marques

Telles

Leal

et al. 2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…The primary outcome will be the severity of depression symptoms evaluated by the MADRS (Montgomery and Asberg, 1979 ), an item with 10 parts to evaluate depressive symptoms. It is one of the most extensively used tools for assessing the degree of PPD in clinical practice (Fernandes et al, 2019 ). Every item of the MADRS is scored on a seven-point scale (from 0 to 6).…”

Section: Outcome Assessmentmentioning

confidence: 99%

Effect of transcranial direct current stimulation on postpartum depression: A study protocol for a randomized controlled trial

Sun

Kang²,

Dong³

et al. 2023

Front. Psychol.

View full text Add to dashboard Cite

Postpartum depression (PPD) is a complex combination of physiological, emotional, and behavioral alterations associated with postpartum chemical, social, and psychological variations. It does harm to the relationship between family members that could potentially last for years. However, standard depression treatments are not ideal for PPD, and the outcomes of these treatments are debatable. Transcranial direct current stimulation (tDCS) is an emerging technology that could provide patients with PPD with a safe and non-pharmacological treatment. tDCS can relieve depression by directly stimulating the prefrontal cortex through the excitatory effect of the anode. It may also ease depression indirectly by promoting the production and release of the neurotransmitter GABA. The mechanism of tDCS makes it an ideal therapeutic approach to treat PPD, although it has not been widely used, and its effect has not been evaluated systematically and effectively. A double-blind, randomized controlled trial will be conducted involving 240 tDCS-naive patients with PPD, who will be randomly divided into two groups. One group will receive routine clinical treatment and care with active tDCS, and the other group will receive routine clinical treatment and care with sham tDCS. Each group of patients will receive a 3-week intervention during which they will receive 20 min of active or sham tDCS 6 days per week. The Montgomery–Åsberg Depression Rating Scale will be administered before the intervention as a baseline and on each weekend throughout the intervention phase. Before and after the intervention, the Perceived Stress Scale and the Positive and Negative Affect Schedule will be evaluated. Side effects and abnormal reactions will be recorded during each treatment. As antidepressants are banned in the study, the results will not be affected by drugs and will therefore be more accurate. Nonetheless, this experiment will be conducted in a single center as a small sample experiment. Therefore, future studies are required to confirm the effectiveness of tDCS in treating PPD.

show abstract

“…O estudo utilizou como instrumentos de mensuração (resumo na Tabela 1): Possui estudo de confiabilidade e validade no Brasil (Fernandes F et al, 2019). Foi aplicada para mensurar o desfecho primário 3x por semana no primeiro mês (FII), 1x…”

Section: Instrumentos De Mensuraçãounclassified

Comparação de eficácia da cetamina intramuscular e da combinação escitalopram e aripiprazol no tratamento agudo e manutenção da depressão resistente: ensaio clínico duplo cego, controlado com placebo, randomizado e de grupos paralelos

Cigognini¹

View full text Add to dashboard Cite

SIGMA-VB: Validity and reliability of the Brazilian Portuguese version of the Montgomery-Åsberg Depression Rating Scale using the Structured Interview Guide for the MADRS

Cited by 10 publications

References 30 publications

Esketamine for Unipolar Major Depression With Psychotic Features

Esketamine for Unipolar Major Depression With Psychotic Features

Effect of transcranial direct current stimulation on postpartum depression: A study protocol for a randomized controlled trial

Comparação de eficácia da cetamina intramuscular e da combinação escitalopram e aripiprazol no tratamento agudo e manutenção da depressão resistente: ensaio clínico duplo cego, controlado com placebo, randomizado e de grupos paralelos

Contact Info

Product

Resources

About